Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer.

By K. Rikova, A. Guo, Q. Zeng, A. Possemato, Jian Yu, H. Haack, J. Nardone, Kimberly A. Lee, C. Reeves, Y. Li and 20 more. Cell, 2007

2,356 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer (2010, background): “Another 5% of tumours harbour translocations in anaplastic lymphoma kinase ( ALK”
The cancer biomarker problem (2008, background): “Indeed, in global surveys of the phosphotyrosine-containing proteome in lung cancer, previously unidentified protein-tyrosine-kinase fusion proteins were foun”
OncoKB: A Precision Oncology Knowledge Base (2017, background): “For example, while explicit FDA approval of crizotinib in ROS1-rearranged NSCLC did not occur until March 2016, off-label use of crizotinib in ROS1 fusion-positive patients had been considered standard-of-care by several expert groups for some time 70–72 .”
Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer (2014, neutral): “Elevated alanine aminotransferase 3 (6) 2 (4) 2 (4) 7 (14)”
The EML4‐ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild‐type EGFR and KRAS (2009, result): “Data from other series also indicated more frequent involvement in nonsmokers.(12,13,15) Because AD is the most common tumor type in both smokers and nonsmokers, we analyzed the AD subgroup, but the association became nonsignificant (P1⁄4 .”